3,3'-dibromo-4,5,6,4',5',6'-hexamethoxy-diphenic acid dimethyl ester | 19491-04-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 单宁
• 英文名称: 3,3'-dibromo-4,5,6,4',5',6'-hexamethoxy-diphenic acid dimethyl ester
• 英文别名: 3,3'-Dibrom-4,5,6,4',5',6'-hexamethoxy-diphensaeure-dimethylester；4,5,6,4',5',6'-Hexamethoxy-3,3'-dibrom-diphensaeure-dimethylester；Methyl 2-bromo-6-(5-bromo-2,3,4-trimethoxy-6-methoxycarbonylphenyl)-3,4,5-trimethoxybenzoate
• CAS: 19491-04-4
• 化学式: C₂₂H₂₄Br₂O₁₀
• 分子量: 608.235
• InChiKey: QLRSLOGTEPOQNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  108
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  3,3'-dibromo-4,5,6,4',5',6'-hexamethoxy-diphenic acid dimethyl ester 在 氢氧化钾 、 sodium hydroxide 、 铜 作用下， 以 甲醇 为溶剂， 生成 3,3'-Dihydroxy-4,5,6,4',5',6'-hexamethoxy-biphenyl-dicarbonsaeure-(2,2')
  参考文献：
  名称：

  Rapp,U. et al., Chemische Berichte, 1972, vol. 105, p. 222 - 233

  摘要：

  DOI：
• 作为产物：
  描述：

  dimethyl (S)-4,4',5,5',6,6'-hexamethoxydiphenoate 在 盐酸 、 三甲基氯硅烷 、 溴 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 、 乙腈 为溶剂， 反应 104.0h， 生成 3,3'-dibromo-4,5,6,4',5',6'-hexamethoxy-diphenic acid dimethyl ester
  参考文献：
  名称：

  Enantioselective synthesis of α-benzylated lanthionines and related tripeptides for biological incorporation into E. coli peptidoglycan

  摘要：

  我们合成了修饰三肽 (S)-Ala-δ-(R)-Glu-X，其中 X = δ-苄基或δ-(4-叠氮基苄基)兰硫鎓的(R,S)或(R,R)非对映异构体。化学策略涉及 4-MeO-苯基噁唑啉的对映选择性烷基化。烷基化的噁唑啉还原开放，然后进行环化和氧化，最终得到四个 PMB 保护的氨基磺酸盐。随后通过去除 PMB、Boc 保护和半胱氨酸甲酯的区域选择性开环，得到了受保护的镧系元素。这些化合物通过一锅法进一步转化为相应的受保护三肽。经过酯和 Boc 去保护后，这四种三肽被评估为天然三肽 (S)-Ala-γ-(R)-Glu-meso-A2pm 的潜在类似物。对这些化合物进行了评估，以便通过生物合成循环途径将其引入大肠杆菌的肽聚糖中。利用纯化的金霉素肽连接酶（Mpl），成功地从含有δ-苄基兰硫氨酸的三肽体外生物合成了 UDP-MurNAc-三肽。在不同的测试条件下，大肠杆菌 W7 都没有发生生物卟啉化，这可能是由于 C 端氨基酸 Cδ 碳上的苄基过大所致。

  DOI：

  10.1039/c4ob01476f

文献信息

• OPTICALLY ACTIVE AMMONIUM SALT COMPOUND, PRODUCTION INTERMEDIATE THEREOF, AND PRODUCTION METHOD THEREOF
  申请人：Maruoka Keiji

  公开号：US20100041881A1

  公开（公告）日：2010-02-18

  An optically active quaternary ammonium salt compound represented by formula ( 1 ), wherein R 1 represents a halogen, a C 1-8 alkyl which is optionally substituted and which is linear, branched, or cyclic, a C 2-8 alkenyl which is optionally substituted, a C 2-8 alkynyl which is optionally substituted, a C 6-14 aryl which is optionally substituted, a C 3-8 heteroaryl which is optionally substituted, a C 1-8 alkoxy which is optionally substituted and which is linear, branched, or cyclic, or a C 7-16 aralkyl which is optionally substituted; R 2 and R 21 each independently represents hydrogen, halogen, nitro, a C 1-8 alkyl which is optionally substituted and which is linear, branched, or cyclic, a C 2-8 alkenyl which is optionally substituted, a C 2-8 alkynyl which is optionally substituted, a C 6-14 aryl which is optionally substituted, a C 1-8 alkoxy which is optionally substituted and which is linear, branched, or cyclic, or a C 7-16 aralkyl which is optionally substituted; one of combinations of R 1 and R 21 , and R 2 and R 21 , may bond to form a C 1-6 alkylene which is optionally substituted, a C 1-6 alkylenemonooxy which is optionally substituted, or a C 1-6 alkylenedioxy which is optionally substituted; R 3 and R 4 each independently represents hydrogen, a C 6-14 aryl which is optionally substituted, a C 3-8 heteroaryl which is optionally substituted, or a C 7-16 aralkyl which is optionally substituted, with a proviso that R 3 and R 4 are not hydrogen at the same time; R 5 represents hydrogen, halogen, a C 1-8 alkyl which is optionally substituted and which is linear, branched, or cyclic, a C 1-8 alkoxy which is optionally substituted and which is linear, branched, or cyclic, a C 2-8 alkenyl which is optionally substituted, or a C 2-8 alkynyl which is optionally substituted; R 6 represents halogen, a C 1-8 alkyl which is optionally substituted and which is linear, branched, or cyclic, a C 1-8 alkoxy which is optionally substituted and which is linear, branched, or cyclic, a C 2-8 alkenyl which is optionally substituted, or a C 2-8 alkynyl which is optionally substituted, and R 5 and R 6 may bond to form an aromatic ring which is optionally substituted; ring A and ring B do not have a same substituent at the same time; symbols * and ** represent an optical activity having an axial chirality; and X −1 represents an anion.

  一种光学活性的季铵盐化合物，其化学式表示为（1），其中R1代表卤素，C1-8烷基（可选择性取代，线性、支链或环状），C2-8烯基（可选择性取代），C2-8炔基（可选择性取代），C6-14芳基（可选择性取代），C3-8杂环芳基（可选择性取代），C1-8烷氧基（可选择性取代，线性、支链或环状）或C7-16芳基烷基（可选择性取代）；R2和R21各自独立地表示氢，卤素，硝基，C1-8烷基（可选择性取代，线性、支链或环状），C2-8烯基（可选择性取代），C2-8炔基（可选择性取代），C6-14芳基（可选择性取代），C1-8烷氧基（可选择性取代，线性、支链或环状）或C7-16芳基烷基（可选择性取代）；R1和R21的组合之一，以及R2和R21的组合之一，可以结合形成C1-6烷基（可选择性取代），C1-6烷基单氧（可选择性取代）或C1-6烷基二氧（可选择性取代）；R3和R4各自独立地表示氢，C6-14芳基（可选择性取代），C3-8杂环芳基（可选择性取代）或C7-16芳基烷基（可选择性取代），但R3和R4不能同时为氢；R5表示氢，卤素，C1-8烷基（可选择性取代，线性、支链或环状），C1-8烷氧基（可选择性取代，线性、支链或环状），C2-8烯基（可选择性取代）或C2-8炔基（可选择性取代）；R6表示卤素，C1-8烷基（可选择性取代，线性、支链或环状），C1-8烷氧基（可选择性取代，线性、支链或环状），C2-8烯基（可选择性取代）或C2-8炔基（可选择性取代），且R5和R6可以结合形成一个芳环（可选择性取代）；环A和环B在同一时间不具有相同的取代基；符号*和**表示轴手性的光学活性；X^-1表示阴离子。
• OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME
  申请人：NAGASE & COMPANY, LTD.

  公开号：EP1870403A1

  公开（公告）日：2007-12-26

  The present invention provides a chiral phase-transfer catalyst of the following formula (I): The compound (I) can be produced by reacting a 2,2'-dimethylene bromide-1,1'-biphenyl derivative, which can be produced through comparatively small number of steps, with an easily available secondary amine.

  本发明提供了下式（I）的手性相转移催化剂： 化合物(I)可通过 2,2'-二亚甲基溴-1,1'-联苯衍生物与易得的仲胺反应制得，该衍生物可通过相对较少的步骤制得。
• 813. Flavogallol
  作者：J. Grimshaw、R. D. Haworth

  DOI：10.1039/jr9560004225

  日期：——
• OPTICALLY ACTIVE AMMONIUM SALT COMPOUND, PRODUCTION INTERMEDIATE THEREOF AND METHOD FOR PRODUCING SAME
  申请人：Nippon Soda Co., Ltd.

  公开号：EP1854796B1

  公开（公告）日：2016-05-04
• OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME
  申请人：Maruoka Keiji

  公开号：US20090270614A1

  公开（公告）日：2009-10-29

  The present invention provides a chiral phase-transfer catalyst of the following formula (I): The compound (I) can be produced by reacting a 2,2′-dimethylene bromide-1,1′-biphenyl derivative, which can be produced through comparatively small number of steps, with an easily available secondary amine.